Maryland State Retirement & Pension System Has $428,000 Holdings in Moderna, Inc. (NASDAQ:MRNA)

Maryland State Retirement & Pension System cut its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 12.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,107 shares of the company’s stock after selling 2,149 shares during the period. Maryland State Retirement & Pension System’s holdings in Moderna were worth $428,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Theleme Partners LLP lifted its position in Moderna by 1.0% during the fourth quarter. Theleme Partners LLP now owns 7,306,861 shares of the company’s stock worth $303,819,000 after acquiring an additional 72,028 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Moderna by 8.7% during the fourth quarter. The Manufacturers Life Insurance Company now owns 3,341,924 shares of the company’s stock worth $138,957,000 after acquiring an additional 267,990 shares during the last quarter. Northern Trust Corp lifted its position in Moderna by 13.6% during the fourth quarter. Northern Trust Corp now owns 2,959,054 shares of the company’s stock worth $123,037,000 after acquiring an additional 354,871 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Moderna by 12.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock valued at $74,557,000 after buying an additional 285,662 shares in the last quarter. Finally, Voloridge Investment Management LLC raised its position in shares of Moderna by 335.6% in the fourth quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company’s stock valued at $107,727,000 after buying an additional 1,996,003 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MRNA. Evercore ISI set a $32.00 price target on shares of Moderna in a research report on Friday, August 1st. Barclays dropped their price target on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating for the company in a research report on Monday, August 4th. Wells Fargo & Company reiterated an “equal weight” rating on shares of Moderna in a research report on Sunday, July 13th. Cowen began coverage on shares of Moderna in a research report on Sunday, July 13th. They issued a “hold” rating for the company. Finally, William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Monday, June 2nd. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Moderna presently has an average rating of “Hold” and an average target price of $43.59.

Moderna Trading Up 5.0%

Shares of NASDAQ MRNA opened at $28.02 on Friday. The firm’s 50-day moving average price is $29.20 and its 200-day moving average price is $29.51. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $91.99. The firm has a market capitalization of $10.90 billion, a P/E ratio of -3.72 and a beta of 1.83.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. During the same quarter in the prior year, the business posted ($3.33) EPS. The firm’s revenue was down 41.1% compared to the same quarter last year. Equities research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.